Outlook Therapeutics (OTLK) closed at $0.41 on November 13, 2026, down 6.1% from the previous close, on volume of 2,928,686 shares (30-day average 3,435,961).
Data as of November 13, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 11, 2026 | Calendar Call Spread | 20-Nov-26 : 19-Feb-27 0.5 C | 400 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
Globe Newswire (Fri, 9-Oct 8:30 AM ET)
Globe Newswire (Tue, 6-Oct 9:20 AM ET)
Globe Newswire (Thu, 1-Oct 9:01 AM ET)
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
Globe Newswire (Fri, 11-Sep 7:00 AM ET)
Globe Newswire (Thu, 10-Sep 9:10 AM ET)
Globe Newswire (Thu, 27-Aug 4:05 PM ET)
Globe Newswire (Thu, 27-Aug 9:01 AM ET)
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
ACCESS Newswire (Thu, 27-Aug 9:01 AM ET)
Globe Newswire (Fri, 14-Aug 7:15 AM ET)
Market Chameleon (Tue, 16-Jun 7:06 AM ET)
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Outlook Therapeutics trades on the NASDAQ stock market under the symbol OTLK.
As of November 13, 2026, OTLK stock price declined to $0.41 with 2,928,686 million shares trading.
OTLK has a beta of 2.94, meaning it tends to be more sensitive to market movements. OTLK has a correlation of 0.04 to the broad based SPY ETF.
OTLK has a market cap of $100.22 million. This is considered a Micro Cap stock.
Last quarter Outlook Therapeutics reported $9,000 in Revenue and -$.09 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.01.
In the last 3 years, OTLK traded as high as $12.85 and as low as $.16.
The top ETF exchange traded funds that OTLK belongs to (by Net Assets): VTI, VXF.
OTLK has underperformed the market in the last year with a price return of -67.7% while the SPY ETF gained +11.5%. OTLK has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -62.5% and -16.3%, respectively, while the SPY returned -2.1% and -1.9%, respectively.
OTLK support price is $.42 and resistance is $.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OTLK shares will trade within this expected range on the day.
